In the past week, BHVN stock has gone down by -8.75%, with a monthly decline of -3.29% and a quarterly surge of 24.88%. The volatility ratio for the week is 4.49%, and the volatility levels for the last 30 days are 4.36% for Biohaven Ltd The simple moving average for the past 20 days is -5.14% for BHVN’s stock, with a 12.12% simple moving average for the past 200 days.
Is It Worth Investing in Biohaven Ltd (NYSE: BHVN) Right Now?
The stock has a 36-month beta value of 3.95. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BHVN is 88.75M, and at present, short sellers hold a 10.51% of that float. On November 14, 2024, the average trading volume of BHVN was 959.10K shares.
BHVN) stock’s latest price update
The stock of Biohaven Ltd (NYSE: BHVN) has decreased by -2.62 when compared to last closing price of 50.36. Despite this, the company has experienced a -8.75% fall in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-12 that Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA) Troriluzole 200 mg QD dosed orally in patients with SCA met the study’s primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes Statistically significant superiority achieved on 9 consecutive, prespecified primary and secondary endpoints Both the study protocol and statistical analysis plan were submitted to, and reviewed by, the U.S. Food and Drug Administration (FDA) prior to topline data analysis Study designed in discussion with the FDA and utilized Phase 3 data and an external control of matched, untreated SCA subjects from the U.S. Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) in accordance with the FDA’s Guidance on Real-World Evidence (RWE) of effectiveness CRC-SCA external control included contemporaneous natural history data gathered from 2010-2024 Planned New Drug Application (NDA) re-submission in 4Q 2024 Completed clarification meeting with CHMP Rapporteurs in 4Q 2024 and MAA documents are being updated to include the new positive BHV4157-206-RWE study data with broader indication to include all SCA genotypes Taldefgrobep alfa, a myostatin-inhibitor, Phase 3 topline data in spinal muscular atrophy (SMA) in 4Q 2024 and Phase 2 trial protocol in obesity expected in 4Q 2024 Advancing extracellular Molecular Degrader of Extracellular Protein (MoDE) programs 3 additional investigational agents expected to enter Phase 1 studies in the next quarter Anticipate Phase 1 update for BHV-1300, including subcutaneous formulation, before year-end Broad progress with TRPM3 antagonist Initiated pivotal Phase 2 trial evaluating BHV-2100, a TRPM3 antagonist, in the acute treatment of migraine Initiated separate proof of concept study with BHV-2100 in neuropathic pain Patient enrollment continues across 5 Phase 2/3 trials with Kv7 activator, BHV-7000, in epilepsy and mood disorders (bipolar and major depressive disorder (MDD)) with potential for multiple data readouts in 2025 Continued progress with antibody drug conjugate (ADC) portfolio BHV-1510 currently dosing cancer patients in Phase 1/2 study, advancing towards combination dosing of BHV-1510 with Libtayo® in 4Q 2024 NEW HAVEN, Conn., Nov. 12, 2024 /PRNewswire/ — Biohaven Ltd.
Analysts’ Opinion of BHVN
Many brokerage firms have already submitted their reports for BHVN stocks, with Jefferies repeating the rating for BHVN by listing it as a “Buy.” The predicted price for BHVN in the upcoming period, according to Jefferies is $57 based on the research report published on September 16, 2024 of the current year 2024.
Bernstein, on the other hand, stated in their research note that they expect to see BHVN reach a price target of $55. The rating they have provided for BHVN stocks is “Outperform” according to the report published on September 04th, 2024.
Morgan Stanley gave a rating of “Overweight” to BHVN, setting the target price at $58 in the report published on July 24th of the current year.
BHVN Trading at 2.65% from the 50-Day Moving Average
After a stumble in the market that brought BHVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.17% of loss for the given period.
Volatility was left at 4.36%, however, over the last 30 days, the volatility rate increased by 4.49%, as shares sank -4.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.56% upper at present.
During the last 5 trading sessions, BHVN fell by -8.75%, which changed the moving average for the period of 200-days by +11.94% in comparison to the 20-day moving average, which settled at $51.70. In addition, Biohaven Ltd saw 14.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHVN starting from CHILDS JOHN W, who purchase 21,052 shares at the price of $47.50 back on Oct 02 ’24. After this action, CHILDS JOHN W now owns 21,052 shares of Biohaven Ltd, valued at $999,970 using the latest closing price.
Coric Vlad, the Chief Executive Officer of Biohaven Ltd, purchase 21,052 shares at $47.50 during a trade that took place back on Oct 02 ’24, which means that Coric Vlad is holding 861,942 shares at $999,970 based on the most recent closing price.
Stock Fundamentals for BHVN
The total capital return value is set at -2.37. Equity return is now at value -265.45, with -180.09 for asset returns.
Based on Biohaven Ltd (BHVN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -20.8.
Currently, EBITDA for the company is -429.14 million with net debt to EBITDA at 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
To sum up, Biohaven Ltd (BHVN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
